Mobile App

Google Play Apple Store
Pulmonary Arterial Hypertension in Special Populations
Certified CME/CNE Activity - Mini Modules
While PH/PAH is a collection of diseases and conditions with diverse etiologies, the majority of clinical trial data has featured a narrow spectrum of illness. Extrapolating clinical trial data from one population to another group has not been proven to demonstrate similar levels of efficacy or safety. Additionally, within the “traditional” PAH population, the subgroup of males with IPAH/APAH have consistently showed a more-rapid course of illness than females.

These educational Mini Modules will outline the issue of the gender paradox, as well as diagnostic and treatment issues relating to PAH related to liver disease (portopulmonary hypertension), PAH related to drugs and toxins, out-of-proportion PAH associated with chronic obstructive pulmonary disease (COPD), and patients with Group 1 PAH, which includes pulmonary vaso-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH).
Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Harrison W. Farber
Harrison W. Farber, MD
Professor of Medicine
Boston University School of Medicine
Director, Pulmonary Hypertension Center
Boston Medical Center


Pulmonary Arterial Hypertension in Special Populations
Certified CME/CNE Activity - Mini Modules

Harrison W. Farber
Harrison W. Farber, MD
Professor of Medicine
Boston University School of Medicine
Director, Pulmonary Hypertension Center
Boston Medical Center
While PH/PAH is a collection of diseases and conditions with diverse etiologies, the majority of clinical trial data has featured a narrow spectrum of illness. Extrapolating clinical trial data from one population to another group has not been proven to demonstrate similar levels of efficacy or safety. Additionally, within the “traditional” PAH population, the subgroup of males with IPAH/APAH have consistently showed a more-rapid course of illness than females.

These educational Mini Modules will outline the issue of the gender paradox, as well as diagnostic and treatment issues relating to PAH related to liver disease (portopulmonary hypertension), PAH related to drugs and toxins, out-of-proportion PAH associated with chronic obstructive pulmonary disease (COPD), and patients with Group 1 PAH, which includes pulmonary vaso-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH).
Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Harrison W. Farber
Harrison W. Farber, MD
Professor of Medicine
Boston University School of Medicine
Director, Pulmonary Hypertension Center
Boston Medical Center





 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

While PH/PAH is a collection of diseases and conditions with diverse etiologies, the majority of clinical trial data has featured a narrow spectrum of illness. Extrapolating clinical trial data from one population to another group has not been proven to demonstrate similar levels of efficacy or safety. Additionally, within the “traditional” PAH population, the subgroup of males with IPAH/APAH have consistently showed a more-rapid course of illness than females.

These educational Mini Modules will outline the issue of the gender paradox, as well as diagnostic and treatment issues relating to PAH related to liver disease (portopulmonary hypertension), PAH related to drugs and toxins, out-of-proportion PAH associated with chronic obstructive pulmonary disease (COPD), and patients with Group 1 PAH, which includes pulmonary vaso-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH).

Pulmonary Arterial Hypertension in Special Populations

Certified CME/CNE Activity - Mini Modules

Harrison W. Farber
Harrison W. Farber, MD
Professor of Medicine
Boston University School of Medicine
Director, Pulmonary Hypertension Center
Boston Medical Center



20
Supported by an independent educational grant from Gilead Sciences Medical Affairs and United Therapeutics Corporation
Expired Activity
Mini Module
6156
  • Pulmonology
  • Archives
Pulmonology
Change Settings